Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1148861

	registered interest
	date	14/10/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the Explanatory Memorandum to The Human Medicines (Amendment) Regulations 2019, 7.12, whether in the event of a Serious Shortage Protocol being issued for immunosuppressant medicines patients would always be referred back to the prescriber for any decision on their treatment before any therapeutic or generic alternative is supplied.
	tabling member constituency	High Peak
	tabling member printed	Ruth George
	uin	326
	answer	answer is ministerial correction date of answer 22/10/2019 answer text <p>While Serious Shortage Protocols (SSP) in England have the scope to cover all medicines and appliances that are on a National Health Service prescription in primary care, including immunosuppressant medicines, it is clear that an SSP for therapeutic or generic equivalents will not necessarily be suitable for all medicines and patients. For example, where medicines need to be prescribed by brand for clinical reasons, which may be the case for certain immunosuppressant medicines. In these cases, patients would always be referred back to the prescriber for any decision about their treatment before any alternative is supplied.</p><p>Any protocol would however only be introduced if clinicians with expertise in the relevant area think it is appropriate. So, if an SSP for an immunosuppressant medicine was under consideration, this would be agreed with, for example, transplant specialists or other relevant clinicians. Pharmacists will have to use their professional judgment as to whether supplying against the protocol rather than the prescription is appropriate or the patient should be referred to their prescriber.</p><p> </p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 22/10/2019 11:21:30 answering member 4380 label Biography information for Jo Churchill
	tabling member	4662 label Biography information for Ruth George

1143006

	registered interest
	date	02/09/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many Medicines Usage Reviews have taken place in each year since their introduction.
	tabling member constituency	North Tyneside
	tabling member printed	Mary Glindon
	uin	284562
	answer	answer is ministerial correction date of answer 09/09/2019 answer text <p>This data has been extracted from the relevant editions of the National Statistics: ‘General Pharmaceutical Services’ for England, which is published on an annual basis by NHS Digital and compares a rolling 10 years data:</p><p> </p><p>2005/06: 148,195</p><p>2006/07: 559,315</p><p>2007/08: 951,358</p><p>2008/09: 1,397,319</p><p>2009/10: 1,707,139</p><p>2010/11: 2,108,604</p><p>2011/12: 2,434,128</p><p>2012/13: 2,820,415</p><p>2013/14: 3,081,108</p><p>2014/15: 3,183,094</p><p>2015/16: 3,313,309</p><p>2016/17: 3,368,005</p><p>2017/18: 3,381,441</p><p>2018/19: Not yet published</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 09/09/2019 15:17:11 answering member 4380 label Biography information for Jo Churchill
	tabling member	4126 label Biography information for Mary Glindon

1347365

	registered interest
	date	15/07/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will bring forward legislative proposals to require pharmaceutical companies that artificially inflate the cost of their products to make those products more affordable.
	tabling member constituency	Bootle
	tabling member printed	Peter Dowd
	uin	33957
	answer	answer is ministerial correction date of answer 20/07/2021 answer text <p>Anti-competitive behaviour, including excessive pricing, is a matter for the Competition and Markets Authority (CMA). The Department asks the CMA to investigate where it has concerns about abuses of competition law for generic medicines and where companies are found by the CMA to be in breach of the legislation, the Department will seek damages and invest that money back into the National Health Service.</p><p>The Government relies on competition to reduce the prices of generic medicines. This has led to some of the lowest prices in Europe and allows prices to react to the market. The Department has been considering proposals for ways to address high prices of generic medicines and will consult in due course.</p><p>The Department also has powers in the NHS Act 2006 to control the prices of NHS medicines. Prices of branded medicines are controlled through the 2019 Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) and alternative statutory scheme which utilises those powers. VPAS caps branded medicines' sales at an agreed level of growth. Any growth in sales above this level results in payments made by scheme members.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 33956 question first answered 20/07/2021 16:34:26 answering member 4380 label Biography information for Jo Churchill
	tabling member	4397 label Biography information for Peter Dowd

1347363

	registered interest
	date	15/07/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of bringing forward legislative proposals to criminalise the inflation of prices for the NHS by drug companies.
	tabling member constituency	Bootle
	tabling member printed	Peter Dowd
	uin	33956
	answer	answer is ministerial correction date of answer 20/07/2021 answer text <p>Anti-competitive behaviour, including excessive pricing, is a matter for the Competition and Markets Authority (CMA). The Department asks the CMA to investigate where it has concerns about abuses of competition law for generic medicines and where companies are found by the CMA to be in breach of the legislation, the Department will seek damages and invest that money back into the National Health Service.</p><p>The Government relies on competition to reduce the prices of generic medicines. This has led to some of the lowest prices in Europe and allows prices to react to the market. The Department has been considering proposals for ways to address high prices of generic medicines and will consult in due course.</p><p>The Department also has powers in the NHS Act 2006 to control the prices of NHS medicines. Prices of branded medicines are controlled through the 2019 Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) and alternative statutory scheme which utilises those powers. VPAS caps branded medicines' sales at an agreed level of growth. Any growth in sales above this level results in payments made by scheme members.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 33957 question first answered 20/07/2021 16:34:26 answering member 4380 label Biography information for Jo Churchill
	tabling member	4397 label Biography information for Peter Dowd

1144685

	registered interest
	date	04/09/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will publish a list of medicines that are (a) not currently available and (b) in short supply in (i) the West Midlands and (ii) England and Wales.
	tabling member constituency	West Bromwich East
	tabling member printed	Tom Watson
	uin	286675
	answer	answer is ministerial correction date of answer 09/09/2019 answer text <p>The Department receives regular reports from the pharmaceutical industry about issues which may potentially interrupt the supply of medicines that may affect United Kingdom patients and uses a host of tools to help mitigate and manage any issues. From January this year, it became a mandatory requirement that pharmaceutical companies must report this information to us in a timely manner.</p><p>The Department shares regular updates about impending and current medicine supply issues directly with the National Health Service and the devolved administrations and communicates with other networks including patient groups where appropriate. These communications include information about mitigation actions and management plans to ensure affected patients can be managed appropriately. The Department does not share this information publicly.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 09/09/2019 15:01:14 answering member 4380 label Biography information for Jo Churchill
	tabling member	1463 label Biography information for Lord Watson of Wyre Forest

1143008

	registered interest
	date	02/09/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will publish the impact assessment for Medicines Usage Reviews not being included in the new community pharmacy contract.
	tabling member constituency	North Tyneside
	tabling member printed	Mary Glindon
	uin	284565
	answer	answer is ministerial correction date of answer 09/09/2019 answer text <p>In line with other measures around releasing sensitive data in internal Impact Assessments, the final Impact Assessment produced in July 2019 in respect of the new Community Pharmacy Contractual Framework, which did include material relating to ending Medicines Usage Reviews, is not being published at this time.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 09/09/2019 15:26:16 answering member 4380 label Biography information for Jo Churchill
	tabling member	4126 label Biography information for Mary Glindon

1142924

	registered interest
	date	02/09/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what alternative arrangements will be introduced in the new local pharmacy contract to safeguard people taking multiple medications and ensure they receive a regular review of their medication to prevent contraindications.
	tabling member constituency	North Tyneside
	tabling member printed	Mary Glindon
	uin	284342
	answer	answer is ministerial correction date of answer 09/09/2019 answer text <p>Medicines Usage Reviews (MURs) are adherence centred reviews with the community pharmacist in isolation from the prescriber. The new Structured Medication Reviews, offered by clinical pharmacists working in primary care networks (PCNs), will provide a more comprehensive review of a patient’s medication with access to the patient record and with the greater ability of clinical pharmacists to make independent decisions to change medication, if that is the result of a review. It is expected that community pharmacists and practice-based pharmacists will work closely together to optimise medicines usage.</p><p>Recently announced changes to the Community Pharmacy Contractual Framework, include a Medicines Reconciliation Service, through which community pharmacists will be expected to collaborate with PCN pharmacists and prescribers, to ensure patients are clear about changes to their medicines, post-discharge, in line with the National Institute for Health and Care Excellence guideline on medicines optimisation. The Pharmacy Quality Scheme and the general practice Quality and Outcomes Framework Quality Improvement modules incentivise PCNs and community pharmacy to identify those taking high risk medicines and take actions to reduce risks where appropriate.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 09/09/2019 15:31:26 answering member 4380 label Biography information for Jo Churchill
	tabling member	4126 label Biography information for Mary Glindon

1142923

	registered interest
	date	02/09/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of scrapping Medicines Usage Reviews on people who take multiple medications.
	tabling member constituency	North Tyneside
	tabling member printed	Mary Glindon
	uin	284398
	answer	answer is ministerial correction date of answer 09/09/2019 answer text <p>It has not proved possible to respond to the hon. Member in the time available before Prorogation.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 09/09/2019 17:30:47 answering member 4380 label Biography information for Jo Churchill
	tabling member	4126 label Biography information for Mary Glindon

1186522

	registered interest
	date	19/03/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential effect of the NHS Commercial Framework on access to medicines through managed access agreements.
	tabling member constituency	Reigate
	tabling member printed	Crispin Blunt
	uin	32031
	answer	answer is ministerial correction date of answer 27/04/2020 answer text <p>NHS England and NHS Improvement has advised that the Commercial Framework for new medicines remains in draft at this time with publication expected in spring 2020. The Commercial Framework is designed to complement the processes and methods of the National Institute for Health and Care Excellence’s technology appraisal programme which provides direction on when managed access agreements may be appropriate. The framework will promote the opportunities that currently exist and clarify NHS England and NHS Improvement’s involvement within the existing arrangements rather than advising on new opportunities for managed access agreements.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 27/04/2020 13:23:48 answering member 4380 label Biography information for Jo Churchill
	tabling member	104 label Biography information for Crispin Blunt

1314651

	registered interest
	date	13/05/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the annual cost to the NHS of mandating the disposal of all unused returned drugs; and what assessment his Department has made of the feasibility of the NHS re-prescribing unused returned drugs instead.
	tabling member constituency	York Outer
	tabling member printed	Julian Sturdy
	uin	1050
	answer	answer is ministerial correction date of answer 19/05/2021 answer text <p>The NHS had since taken a range of further measures to further optimise the use of medicines and reduce wastage.</p><p>Medicines cannot normally be reused as the quality of returned medicines cannot be assessed on physical inspection alone. The World Health Organization’s guidelines state that if the quality of an item is unacceptable in the donor country, it is also unacceptable as a donation. Moreover, there are patent issues involved in donating medicines to other countries.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 1051 question first answered 19/05/2021 15:16:52 answering member 4380 label Biography information for Jo Churchill
	tabling member	4079 label Biography information for Julian Sturdy